1073-OR: Associations of Early Pregnancy Maternal Glycemic and Metabolic Measures with Newborn Adiposity

Introduction and Objective: This secondary analysis of the GO MOMs cohort evaluated associations of first trimester maternal BMI, CGM, OGTT, HbA1c and metabolic measures with newborn adiposity. Methods: At 9 US centers gravidas with singletons and no pre-existing diabetes underwent 75g OGTT, HbA1c, CGM and fasting lipid measures (free fatty acids-FFA; triglycerides-TG) at 10-14 weeks’ gestation. Insulin sensitivity (IS) and beta cell function (βCF) were calculated. Newborn measures at 72 hours of life yielded estimates of fat mass (FM), percent body fat (%BF), and waist/length ratio (WLR). Linear regression models, adjusted for multiple covariates, assessed associations between first trimester exposures and newborn adiposity. Results were stratified by newborn sex if interaction terms were significant. Results: 1555 (71%) participants had complete measures. In adjusted regression models (Table), for BMI higher by 1 SD, newborn FM was higher by 26g, %BF by 0.54%, and WLR by 0.61. Similarly, for fasting glucose higher by 1 SD, FM was higher by 18.5g, %BF by 0.37%, and WLR by 0.36. Nocturnal and 24hr mean CGM glucose were positively associated with FM and %BF. HbA1c was positively associated with WLR and, in females, FM. IS, βCF, FFA and TG were not associated with any adiposity measure. Conclusion: First-trimester maternal BMI, fasting glucose, CGM-measured glycemia, and HbA1c were positively associated with higher measures of newborn adiposity. Disclosure K. Vesco: None. F.L. Facco: None. M. Feghali: None. W. Grobman: None. A.A. Killeen: None. E. LeBlanc: None. W. Lowe: None. A. Merriam: None. M. Mourad: None. C. Oshiro: None. C. Powe: Research Support; Current; Dexcom, Inc. Other - Associate Editor of Diabetes Care, Honoraria for Educational Materials; Current; American Diabetes Association. Other - Royalties for Up To Date chapters; Current; Wolters Kluwer (Up To Date). Other - Speaker; Ended; Medscape. U. Reddy: None. D. Rouse: None. D. Scholtens: None. J. Sherr: Other - research support, consultant, advisory board member; Current; Abbott Diabetes. Other - advisory board member, consultant; Current; Vertex Pharmaceuticals Incorporated. Consultant; Current; Ypsomed AG. Research Support; Current; Dexcom, Inc., JDRF, Provention Bio, Inc., National Institutes of Health. Other - research support, consultant, advisory board member; Current; Insulet Corporation, Medtronic. Research Support; Current; Sanofi. Advisory Panel; Current; sequel med tech. A.C. Spadola: None. E. Werner: None. L.M. Yee: None. N. Zork: None. N. Lancki: None. P. Catalano: None. Funding The GO MOMs study is supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases. U01DK123795 to Massachusetts General Hospital; U01DK123791 to Kaiser Permanente; U01DK123759 and U01DK123745 to Northwestern University; U01DK123799 to Yale University; U01DK123783 to Women & Infants Hospital of Rhode Island. Dexcom provided the CGM systems used in the study free of charge.